Tumorigenesis is a complex process that is heterogeneous and affected by numerous sources of variability. This study presents a stochastic extension of a biologically grounded tumor growth model, referred to as the Norton-Simon-Massagué (NSM) tumor growth model. We first study the uncontrolled version of the model where the effect of chemotherapeutic drug agent is absent. Conditions on the model's parameters are derived to guarantee the positivity of the tumor volume and hence the validity of the proposed stochastic NSM model. To calibrate the proposed model we utilize a maximum likelihood-based estimation algorithm and population mixed-effect modeling formulation. The algorithm is tested by fitting previously published tumor volume mice data. Then, we study the controlled version of the model which includes the effect of chemotherapy treatment. A closed-loop control strategy that relies on model predictive control (MPC) combined with extended Kalman filter (EKF) is proposed to solve an optimal cancer therapy planning problem.
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I. INTRODUCTION
The understanding of the underlying mechanisms of cancer is one of the great challenges of modern medicine. Despite the efforts that are being made to understand the many processes and mechanisms driving cancer and also to improve the efficacy of current treatments, much remains to be done to fight this lethal disease. Mathematical modeling is a powerful tool that is extensively used to describe realworld problems illuminating different disciplines of science and engineering, including oncology [1] . Several oncological mathematical models have proven to be useful in providing guiding principles for better elucidating the complex biological processes and mechanisms underlying cancer growth. These models have also shown to be of potential help in the quest of optimal therapy scheduling [2] , for the ultimate purpose of approaching towards personalized cancer therapy.
Different mathematical models for tumor growth have been proposed in the last decades. Those models can be arranged in a broad spectrum ranging from simple macroscopic models trying to emulate the clinically observed tumor volumes to more sophisticated models involving the microscopic 1 and/or molecular processes that contribute to tumor growth [3] , [4] , [1] . A plethora of macroscopic tumor growth models, based on ordinary differential equations (ODEs) exist in the literature including those based on logistic, Gompertezian, and Von Bertalanffy models; see [5] , [1] and the references therein. However, it should be stressed that often real tumor growth data is not smooth and discrepancies exist between the measured data and the ones simulated from theoretical deterministic models. In fact, deterministic models do not account for the different sources of variability, often not quantifiable or even unknown, that are natural to the process of tumor growth. A possible approach to take into account the different sources of variability is to add a noise term to a given deterministic ODE model, which leads to a stochastic differential equation (SDE) model. This class of models has been used to describe the tumor growth, e.g., in [6] , [7] .
Modeling the effect of cytotoxic chemotherapy on tumor growth dynamics has seen several important developments in the past several decades. Furthermore, the question of identifying the optimal anti-cancer chemotherapeutic treatment for a specific patient is fundamental, yet challenging to answer conclusively. It is recognized in both the scientific and clinical communities that the empirical clinical practice for scheduling chemotherapy has many limitations. There is, therefore, a need to optimize current chemotherapy schedules for cancer to enable personalized healthcare. Towards this end, approaches based on control systems engineering have been developed for the automation of chemotherapy treatment [8] , [9] , [10] , [11] , [12] . These in silico trials do not need the huge costs of laboratory experiments and can also be tested in a relatively fast time.
Even though several techniques have been proposed to address the control and identification problems associated with different tumor growth models, to the best of our knowledge, this is the first study that considers the analysis of a stochastic version of the so-called "Norton-Simon-Massagué" (NSM) tumor growth model, a biologically grounded minimal order model, for the purpose of estimation and control. We aim ultimately to find general guiding principles from the proposed stochastic NSM tumor growth model using tools from identification and control theories.
The remainder of this paper is organized as follows. Section II describes a general stochastic extension of the deterministic NSM tumor growth model in the absence of therapy, along with conditions on the model's parameters that guarantee the positivity of its solution. In Section III, the estimation algorithm used to calibrate the proposed unperturbed stochastic model is provided along with some simulation results showing the performance of the algorithm. The effect of the chemotherapy drug agent is included to the unperturbed model in Section IV where an MPC-based strategy is proposed to solve an optimal therapy scheduling problem. Concluding remarks are provided in Section V.
II. UNCONTROLLED STOCHASTIC

NORTON-SIMON-MASSAGUÉ TUMOR GROWTH MODEL
In this section, we present a stochastic extension of the uncontrolled deterministic NSM model to account for the different sources of random effects that are inherent in the complex and heterogeneous process of tumor growth.
A. Model description
A growth model of the form
was proposed in the fifties to describe the growth of biological organisms based on basic energetic principles [13] .
The parameters a and b are the anabolism (growth) and catabolism (death) constants respectively. Equation (1) states that the net growth rate of an organism results from the balance of synthetic and degradative processes. While the rate of the former process follows a law of allometry (i.e., the rate is proportional to the volume V (t) via a power function), the rate of the latter process scales linearly with V (t).
The two special cases of (1), (i) power law b = 0, and (ii) second type growth α = 2/3 have already been successfully applied to describe tumor growth [14] , [15] . The general case, 0 < α < 1, was introduced in [16] to explain the selfseeding hypothesis. Moreover, a geometrical interpretation was provided in [17] , [5] . It relates the exponent α = d/3 to the fractional Hausdorff dimension of the proliferative tissue, where d denotes the fractal dimension of proliferative tissue. Furthermore, in 2011, model (1) was derived mechanistically by linking tumor growth to metabolic rate and vascularization [18] . In the rest of the paper, we will refer to model (1) as the deterministic NSM tumor growth model 1 .
To consider the intertumor and intratumor heterogeneity in the tumor growth process, we propose to extend the deterministic ODE model (1) to a more general stochastic version, where the different types of randomness are modeled in the diffusion term of (2). The time evolution of the tumor volume in the absence of therapy is described by the following SDE of Itô-type:
driven by a standard Wiener process (W (t) : t ≥ 0) and started at V 0 ∈ R * + , where a, b, α, σ , β are positive real parameters. The proposed stochastic generalization (2) encompasses the cases of β = α and β = 1 that can be interpreted as random versions resulting from randomly perturbing the growth and death parameters (a and b) of the deterministic model by Gaussian distributions.
B. Regularity of the solution on R * + An important property that makes SDE (2) valid in describing the dynamics of tumor volumes is the invariance of the solution (V (t) : t ≥ 0) with respect to R * + (set of all strictly positive real numbers). Theorem 1 provides conditions on the parameters of model (2) that guarantee the positivity of the solution V (t).
Theorem 1:
Proof: Due to page limitation, we refer the interested reader to the extended version of the paper [19] for the full technical details about the proof.
III. CALIBRATION OF THE UNCONTROLLED STOCHASTIC NSM GROWTH MODEL
The stochastic NSM tumor growth model is usually not entirely known a priori since information about the model's parameters may be missing. It is, therefore, essential to develop an efficient estimation algorithm to extract estimates of the model's parameters from the available tumor volume measurements. In this section, details about a maximum likelihood estimator (MLE) based algorithm are provided along with numerical results showing its performance.
A. Population mixed-effect modeling approach
When only sparse data measurements are available for several individuals from a population, which is the case for tumor volume data, one can use the population mixed-effect modeling approach [20] to estimate the parameters of the investigated model. This framework encompasses two stages. The first stage describes the intra-individual variability, while the second stage models the inter-individual variations. The calibration of such class of models is performed by pooling the time series data of all subjects into a single larger measurement set which may potentially resolve identifiability issues when only a few data points are available per subject.
Let us consider the following population mixed-effect NSM tumor Growth model, for i = 1, ..., N and
where i = 1, 2, ..., N denotes the number of individuals in a population, j = 1, 2, ..., M represents the number of time point measurements and ε i j ∼ N (0, S) is the measurement noise assumed to be Gaussian with zero mean and covariance S. In this work, we assume that the inter-individual variability comes from the initial condition which is given as follows
where G(.) is a nonlinear mapping defined in Remark 1, V M i0 is the fixed effect initial condition for the volume, and η i is the random effect parameter that describes the variation of each individual from the population value V M i0 . Thus, the full model's parameters to be estimated are defined in Θ = (θ , Ω 1 ), where θ = (a, b, α, σ , S, β ,V M i0 ) is the vector of the fixed effect parameters.
B. Estimation algorithm
The estimation algorithm used in this paper is based on the MLE combined with the EKF. We provide in the following the main steps of the estimation algorithm, and for more details we refer the reader to [21] and references therein.
The population likelihood function for fixed-effects is defined as
where N is the number of individuals, Y i is the vector of all observations for the i th individual, (θ , η i , Ω 1 ) are the parameters defined in the previous subsection, p(Y i |θ , η i ) is the probability for the first stage model, p(η i |Ω 1 ) is the probability related to the second stage that relates the random effects to the inter-individual variation, and l i is the a posteriori log-likelihood function.
Often the population likelihood function (5) cannot be computed analytically and therefore needs to be approximated. In [21] , the a posteriori log-likelihood function l i is approximated by a second-order Taylor expansion around η * i , the maximizer of l i . The population likelihood function to be maximized is given as follows [21] :
where the second derivative ∆l * i is approximated using firstorder conditional estimation method:
with ε i j = ∂ ∂ η i ε i j | η * i , and the output error residual ε i j and conditional residual covariance R i( j| j−1) of individual i are computed using the EKF.
The optimization of the population likelihood function (6) is nested in the sense that approximation (7) depends on the optimal random effect η * i , the optimizer of l i . This estimation approach is implemented in the statistical programming language R within Population Stochastic Modeling (PSM) package [21] .
Remark 1: Because the EKF cannot handle SDEs with state-dependent diffusion terms, we apply Lamperti transformation [22] to remove the state dependence from the diffusion term of (3). The resulting transformed model is given as follows, for i = 1, 2, ..., N, and j = 1, 2, ..., M,
• Case 1: β = 1:
whereZ(t) = ln[V i (t)], and ln[.] is the natural logarithmic function .
C. Results
1) Data description:
We consider tumor volume data from an ectopic syngeneic tumor (Lewis lung carcinoma). These data, which were published in [5] , were downloaded from the webpage of Sébastien Benzekry 2 . For more details about mice experiments, one can refer to the latter reference. The temporal profiles of the volume data are depicted in Figure 1 , where the population group contains eight subjects. 2) Fitting results: The calibration of the growth model (9) with multiplicative noise is performed by fitting the data shown in Figure 1 . The initial values of the algorithm were selected through a trial and error strategy, and the available data is specified to the algorithm in the log-domain.
The values of the parameter estimates and their 95 % confidence intervals (CIs) are given in The behavior of the identified model using its corresponding estimated parameter values was examined through the output one-step predicted and smoothed estimates as shown in Figure 2 for two individuals within the population. Both types of state estimates are based on the EKF, where the predicted estimate uses observation up to t k−1 to predict the output at t k and the smoothed estimate uses all observations at each time point. The smoothed output is the optimal type of estimates because all the available data is used to estimate the tumor volume at a specific time instant, and this can be clearly observed from Figure 2 . Fitting results of the other subjects in the population can be found in the extended version of the paper [19] . 
IV. CONTROLLED STOCHASTIC NSM GROWTH MODEL
The log-kill hypothesis, which posits that a given dose of chemotherapy kills the same fraction of tumor cells regardless of the size of the tumor at the time of administration [23] , has for decades guided the clinical treatment of many types of cancer. This model led to the administration of maximum tolerated dose (MTD) of a cytotoxic agent with prolonged treatment breaks to counteract disease progression and to kill as many cancer cells as possible while allowing the body to recover from the induced treatment toxicity. This regimen worked experimentally for haematological cancers (leukemia) [23] , but it failed with many types of solid tumors. Based on clinical observations that were not in agreement with the outcomes of log-kill hypothesis, the Norton-Simon hypothesis emerged [24] , [25] . It states that cancer cell death in response to chemotherapeutic drug agent is proportional to the untreated tumor growth rate at the time of treatment. This model led to the finding that not only dose intensity is important but also dose density.
In this section, we model the effect of chemotherapy drug agent into the unperturbed stochastic growth model (2) following the Norton-Simon hypothesis.
A. Mathematical model
Mathematically, the controlled stochastic NSM model is formulated by the following equation:
where ξ reflects the sensitivity of the tumor to the drug whose concentration is denoted C(t). The dynamics of the drug concentration C(t) is described using the onecompartment pharmacokinetics model [26] given as follows
where u(t) represents the rate of flow of drug into the body, and k is the elimination rate constant of the drug from bloodstream. The elimination half-life of the drug can be computed as t 1/2 = ln(2)/k. Before we formulate and solve the closed-loop optimal control problem (OCP) associated with chemotherapy scheduling, we point out that we conducted a comparative study between different chemotherapeutic protocols in openloop standpoint. For further details we refer the interested reader to the extended version of the paper [19] .
B. Closed-loop optimal dosing strategy
In this subsection, we aim to solve an OCP in a feedback manner to plan chemotherapy for cancer treatment. In order to do so, we use the MPC approach combined with the EKF for state estimation. The MPC method, also known as receding horizon control, is a feedback control strategy that was developed since the seventies and has been successfully applied to various fields [27] . The control input in MPC is determined by solving at each sampling instance an openloop finite-horizon OCP.
To design the control therapy plan, we use the same uncontrolled model identified in Section III combined with a cytotoxic drug effect. The state-space representation of the controlled stochastic NSM tumor growth model to be used in the OCP formulation is given as follows:
where the state-space vector is
The values of the stochastic tumor growth model are the ones identified earlier using lung data and given in Table I . The elimination rate constant for the drug is k = 1 day −1 .
The objective is to find the optimal u(t) that reduces the volume of cancer cells around a tolerable target volume value 3Z * while minimizing the effects of toxicity by constraining the amount of injected drug dose in U . The optimal control problem to be solved is thus given as follows (see Figure 3 for a schematic diagram):
where T p is the prediction horizon and the parameters q 1 and q 2 weight the relative importance of reducing the tumor volume and using less drug. The filtered statex k|k is estimated using the EKF. As it can be seen from (14) and Figure 3 , the design of the controller is constrained by a deterministic transformed NSM tumor growth model and tested on its stochastic counterpart. It is worth noting however that the solved OCP includes information about the noise level in the deterministic transformed dynamics, which is due to the applied Lamperti transformation. The numerical solution of the OCP (14) is performed using the direct collocation method [28] , [29] . The control input is assumed piecewise constant and parametrized as follows,
where {τ i } n i=0 , s.t., τ 0 = t k and τ n = t k + T p , are the global collocation points, that define the local collocation points {γ i } m i=0 , s.t., γ 0 = 0 and γ m = 1. Clinical chemotherapy dosing differs from the proposed synthetic control systems technique in the manner of drug delivery. The designed control input is assumed to be piecewise constant, while the chemotherapeutic drug many times is not administrated continuously, but, e.g., as intravenous bolus. So, the values of the designed controller at the collocation points can be considered as the bolus injection dosage.
The simulation results were based on the Python code that was made available in "https://github.com/niclasbrok/nmpc vdp".
The code uses PyIpopt that allows to interface with Ipopt, which is an optimization software library, via Python. We choseV * = 25 mm 3 , q 1 = 100, q 2 = 1 and V (0) = 1000 mm 3 ∼ 10 9 cells corresponding to the size assumed to be clinically detectable, which were set in previous studies as well, e.g., in [11] . The prediction horizon T p = 10 days, and the total simulation period is fixed to 140 days. The allowable toxicity interval is chosen to be U = [0, 10]. Figure 4 shows the optimal therapy schedules for the case where volume measurements are available every 7 days. The global and local collocation points that define the subintervals of u(t) are chosen as n = 10 and m = 10 respectively. The numerical results obtained suggest that an optimal chemotherapy plan that reduces the size of the tumor while minimizing the toxicity can be achieved by allowing the doses to vary during the treatment in response to the status of the tumor. This type of plans is not the standard of care in clinics yet but fits nicely to the type of adaptive therapy that is being a high field of investigation [30] . To assess the robustness of the proposed feedback control strategy to errors in the parameter values, we perturb the values of the parameters in the NSM model block while keeping the nominal values identified earlier for the dynamic optimization (MPC) and the estimator (EKF) blocks. The control parameters are kept the same as earlier. Figures 5-7 show a certain degree of robustness against variations in growth parameters at the price of slower convergence. Moreover, the robustness is stronger when varying the growth and death parameters, a and b, compared to the power law parameter, α. In the present work, we investigated and analyzed a stochastic model describing the growth of cancerous cells at the macroscopic level. The model was extended from a mechanistic, deterministic model to account for the intrinsic and extrinsic sources of variability in the tumor growth process. We studied two variants of the proposed stochastic model, the unperturbed version where the growth is in the absence of drug agents and the perturbed version in which the control drug is included.
We believe that the results we derived so far are promising in providing guiding principles which will hopefully allow for an increased understanding of the tumor growth process and also for designing improved therapy plans. Future investigations should be carried out to address some important issues towards possible clinical applications of the proposed stochastic uncontrolled/controlled tumor growth model. First, validating the proposed stochastic NSM model using a larger tumor volume datasets is essential to find correlates between the parameter estimates for different types of cancer. A great emphasis should be given to the parameter α, which is believed to be related to the density of tumor tissue. Regarding the controlled model, it is worth solving the stochastic closed-loop OCP, where probabilistic descriptions of uncertainties are incorporated into the OCP formulation.
